Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

No longer afraid of the dentist.

Teaching robot with piezo technology

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Mercodia AB

A vaccine the world is waiting for: “It can change the lives of many”

A Solna laboratory is developing a vaccine that could save the lives of countless children in low- and middle-income countries. “Working on something that can m...

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Medicon Valley Alliance

Revealing the secrets of a part

CT inspection in automation technology at Festo.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Swedish team tests Alzheimer antibody for brain imaging

Recent breakthroughs in Alzheimer’s treatment have increased the need for precise diagnostics in the field. Researchers in Uppsala are working to develop improv...

DBB ventiler: Snabbare installationer och färre skarvar

Spirax Sarco Safebloc är en lösning med en unik platsbesparande design som innebär snabbare installation och färre skarvar. Spirax

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Spatial Biology Studies in Lung Tissue using Spectral Microscopy

Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.